	Application No.	Applicant(s)
Notice of Allowability	09/434,382	TAVTIGIAN ET AL.
	Examiner	Art Unit
	Anne Holleran	1642
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS I herewith (or previously mailed), a Notice of Allowance (PTOL-8 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	S (OR REMAINS) CLOSED i 5) or other appropriate comm RIGHTS. This application is	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to <u>5/19/2004</u> .		
2. \boxtimes The allowed claim(s) is/are $\underline{1-3,11-15,61-63,67-77}$ and $\overline{7}$	<u>9-82</u> .	
3. \square The drawings filed on $___$ are accepted by the Examin	ner.	
4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: 1. Certified copies of the priority documents hat 2. Certified copies of the priority documents hat 3. Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	ve been received. ve been received in Applicati	on No
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be sub INFORMAL PATENT APPLICATION (PTO-152) which g		
CORRECTED DRAWINGS (as "replacement sheets") m (a) ☑ including changes required by the Notice of Draftsper 1) ☐ hereto or 2) ☑ to Paper No./Mail Date 2/28 (b) ☐ including changes required by the attached Examined Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in 7. ☐ DEPOSIT OF and/or INFORMATION about the department of the partment of the pa	erson's Patent Drawing Review/2001. er's Amendment / Comment of 1.84(c)) should be written on the header according to 37 Cloosit of BIOLOGICAL MAT	the drawings in the front (not the back) of FR 1.121(d). ERIAL must be submitted. Note the
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SE Paper No./Mail Date 5/19/2004) 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	6. ⊠ Interview S Paper No. 3/08), 7. ⊠ Examiner's	LARRIS, PH.D.
	-	PRIMARY EXAMINER

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jeffrey Ihnen on August 13, 2004.

The application has been amended as follows:

In the claims:

Claim 76. A method of producing a polypeptide encoded by [SEQ ID NO: 1 comprising mutation 1641 ins G which comprises] a nucleic acid comprising SEQ ID NO: 1, wherein G is inserted between bases 1641 and 1642, comprising (i) culturing host cells containing an expression vector encoding said polypeptide under conditions suitable for production of said polypeptide and (ii) recovering said polypeptide.

Any inquiry concerning this communication or earlier communications from the Office should be directed to Anne Holleran, Ph.D. whose telephone number is (571) 272-0833. Examiner Holleran can normally be reached Monday through Friday, 9:30 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew, can be reached at (571) 272-0787.

Application/Control Number: 09/434,382 Page 3

Art Unit: 1642

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 571-1600.

Anne L. Holleran Patent Examiner August 13, 2004